Latest Articles

Publication Date
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis - Newswise

Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis Newswise

Published: May 14, 2026, 12:40 p.m.
Terazosin as a Non-Hormonal Treatment for Endometriosis.

Endometriosis is a chronic, estrogen-dependent inflammatory disease including aberrant local steroidogenesis, inflammation, angiogenesis, oxidative stress, and prostaglandin-mediated pain. Given the elevated adrenergic receptor expression in endometriotic lesions and the potential …

Published: May 2, 2026, midnight
Clinical and endocrine effects of pharmacological therapy in endometriosis: a systematic review and meta-analysis.

Endometriosis, PCOS, adenomyosis, and dysmenorrhea are major illnesses. Hormonal as well as non-hormonal treatments were evaluated for COCs, progestins, GnRH analogues, LNG-IUS, relugolix, and adjunctive therapies. These treatments resulted in …

Published: April 1, 2026, midnight
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - Digital Journal

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis Digital Journal

Published: March 18, 2026, 12:41 p.m.
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - ACCESS Newswire

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis ACCESS Newswire

Published: March 18, 2026, 10:13 a.m.
FinancialContent - Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - FinancialContent

FinancialContent - Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis FinancialContent

Published: March 18, 2026, 10 a.m.
H2S-Releasing Aspirin Nanoparticles Alleviate Endometriosis and Associated Anxiety.

Despite ongoing challenges in developing effective non-surgical and non-hormonal treatments for endometriosis, the psychological manifestations of the disease-particularly anxiety-remain comparatively underexplored. In this study, a hydrogen sulfide (H2S)-releasing aspirin derivative, …

Published: Feb. 8, 2026, midnight
An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target.

Endometriosis is a chronic, heterogeneous disease with limited non-hormonal treatment options. Drug repurposing provides an accelerated route to identify safe, tolerable, and potentially effective therapies for endometriosis. Receptor tyrosine kinase-like …

Published: Dec. 3, 2025, midnight
Integrative microbiome-metabolomics identifies Pseudomonas as a potential pathogenic factor in endometriosis.

Endometriosis (EMS) is a chronic disease characterized by unclear etiology, influenced by various genetic and environmental factors, with no definitive biomarkers available for early screening. Recent studies suggest that the …

Published: Oct. 30, 2025, midnight
A Dual-Targeted Liposomal Nanosystem for Co-Delivery of Estrogen Receptor β Antagonist and Disulfiram for the Non-Hormonal Treatment of Endometriosis.

Endometriosis is an estrogen-dependent disease that severely affects the physical and mental health of women of childbearing age. Due to the significant side effects of traditional hormone therapies, non-hormonal treatment …

Published: Oct. 29, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!